Pierro Maria, Chioma Roberto, Włodarczyk Krzysztof, Benke Margit, Mangroo Kaushik, Vetrano Maria Chiara, Zielińska Kinga, O'Keeffe David, Seliga-Siwecka Joanna, Purtill Helen, Al-Assaf Niazy, Villamor Eduardo, Philip Roy K
Division of Neonatology, Department of Paediatrics, University Maternity Hospital Limerick, V94 C566 Limerick, Ireland.
Neonatology Unit, Ospedale Isola Tiberina, Gemelli Isola, 00186 Rome, Italy.
Children (Basel). 2025 Sep 16;12(9):1238. doi: 10.3390/children12091238.
Evidence on steroid treatment for established bronchopulmonary dysplasia (BPD) is sparse. To our knowledge, a systematic review has never been conducted on this topic. This meta-analysis aims to synthesize available evidence for the use of postnatal steroids to treat established BPD. MEDLINE, Embase, Cochrane databases, and gray literature sources were searched without time or language restrictions until October 2024. We included randomized and non-randomized trials (analyzed separately) that evaluated postnatal steroids started from 28 days of life in preterm infants diagnosed with BPD. Certainty of evidence was assessed using the GRADE approach. The search retrieved 9113 records, and 20 studies were included. Meta-analysis of the RCTs demonstrated that steroids significantly reduced oxygen requirement (daily mean difference of 1.6%, 95% CI 0.25-2.95), but the analysis did not identify significant differences in total duration of supplemental oxygen, length of stay, or mortality (moderate quality). From a safety perspective, steroids resulted in a transient increase in systemic blood pressure (mean difference of 6.8 mmHg, 95% CI 4.6-8.9) (moderate quality). Weight gain during treatment was lower in the systemic steroid group (-9.2 g/day, 95% CI -11.7 to -6.8) (moderate quality), although overall growth was reported as equal (2.4 g/day, 95% CI -0.3 to 6.3) (moderate quality). One retrospective study reported the incidence of steroid treatment among infants with established BPD (any definition) to be as high as 36%. Two single-arm studies reported a prolonged high-dose systemic steroid regimen as the routine treatment strategy for severe established BPD. Moderate quality of evidence suggests that steroid treatment cannot be recommended as standard of care for established BPD. However, corticosteroids are often used to this end. Large-scale RCTs designed to treat BPD are urgently needed. Furthermore, careful consideration for patient selection and compliance with GRADE methodology is essential.
关于已确诊支气管肺发育不良(BPD)的类固醇治疗的证据稀少。据我们所知,从未针对该主题进行过系统评价。本荟萃分析旨在综合现有证据,以支持产后使用类固醇治疗已确诊的BPD。检索了MEDLINE、Embase、Cochrane数据库和灰色文献来源,检索时间无限制,语言不限,直至2024年10月。我们纳入了随机和非随机试验(分别分析),这些试验评估了出生28天后开始使用的产后类固醇对诊断为BPD的早产儿的疗效。使用GRADE方法评估证据的确定性。检索共获得9113条记录,纳入了20项研究。随机对照试验的荟萃分析表明,类固醇显著降低了氧气需求(每日平均差异为1.6%,95%可信区间为0.25 - 2.95),但分析未发现补充氧气的总时长、住院时长或死亡率存在显著差异(证据质量中等)。从安全性角度来看,类固醇导致系统性血压短暂升高(平均差异为6.8 mmHg,95%可信区间为4.6 - 8.9)(证据质量中等)。全身类固醇组治疗期间的体重增加较低(-9.2 g/天,95%可信区间为-11.7至-6.8)(证据质量中等),尽管总体生长情况报告为相同(2.4 g/天,95%可信区间为-0.3至6.3)(证据质量中等)。一项回顾性研究报告称,已确诊BPD(任何定义)的婴儿中类固醇治疗的发生率高达36%。两项单臂研究报告了延长高剂量全身类固醇方案作为重度已确诊BPD的常规治疗策略。中等质量的证据表明,类固醇治疗不能作为已确诊BPD的标准治疗方法推荐。然而,皮质类固醇经常为此目的使用。迫切需要设计用于治疗BPD的大规模随机对照试验。此外,仔细考虑患者选择并遵循GRADE方法至关重要。